Publications by authors named "P Margaron"

Claim this Profile
O
Outcomes by Faricimab Treatment Interval at Week 48 of TENAYA-LUCERNE Phase III Trials in Neovascular Age-Related Macular Degeneration.
Nikolas J S London, Chui Ming Gemmy Cheung, Stephan Michels, Aachal Kotecha, Philippe Margaron

Ophthalmol Retina· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anatomic Outcomes with Faricimab vs Aflibercept in Head-to-Head Dosing Phase of the TENAYA/LUCERNE Trials in Neovascular Age-related Macular Degeneration.
Chui Ming Gemmy Cheung, Jennifer I Lim, Siegfried Priglinger, Giuseppe Querques, Philippe Margaron

Ophthalmology· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Emerging clinical evidence of a dual role for Ang-2 and VEGF-A blockade with faricimab in retinal diseases.
Varun Chaudhary, Florie Mar, Manuel J Amador, Andrew Chang, Kara Gibson, Philippe Margaron

Graefes Arch Clin Exp Ophthalmol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disease Activity Criteria Impact Dosing Interval Assignment in Neovascular Age-related Macular Degeneration Trials.
Marco A Zarbin, Christina Y Weng, Nikolas J S London, Adrian Hock Chuan Koh, Roberto Gallego-Pinazo, Philippe Margaron

Ophthalmol Retina· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Baseline characteristics associated with the first year treatment interval of intravitreal faricimab in neovascular age-related macular degeneration (nAMD).
Parth Shah, Neala Rafijah, Yannan Tang, Sobha Sivaprasad, Thibaud Mathis, Philippe Margaron

BMJ Open Ophthalmol· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis